PACT Pharma

PACT Pharma is an exciting, well-funded clinical stage company with facilities and laboratories in South San Francisco, CA. PACT is developing personalized adoptive T cell therapies for the eradication of solid tumors. We are in the San Francisco bay area, in the heart of the world?s premier biotechnology research hub. PACT Pharma offers a competitive compensation and benefits package, including aggressive participation in the growth of the company in the form of stock option grants. PACT is developing tumor-mutation targeted T Cells tailored for each patient. Tumor mutation (neoE) targeting is programmed into the patient?s own T cells to seek out & kill the tumors. Using (non-viral) precision genome engineering, the neoE-targeted Tcell receptors (TCRs) replace the endogenous TCR of fresh CD8 and CD4 T cells collected from that same patient followed by minimal expansion in closed systems for re-infusion into the patient. These patient-specific neoTCR-P1 cells are formulated to immediately kill all neoantigen-expressing tumors, together with a deep reservoir of ?ready-to-go? neoTCR-P1 cells for long term persistence and capable of rapid expansion to prevent future cancer recurrence. Mission:?Our mission is to leverage technology developed in the laboratories of Jim Heath and David Baltimore to advance the feasibility, affordability and clinical utilization of personalized neoantigen-specific adoptive cell therapy for cancer.